Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma (IPHA) has announced compelling long-term follow-up data from the Phase 2 TELLOMAK trial evaluating lacutamab in treating Sézary syndrome (SS) and mycosis fungoides (MF). The trial demonstrated significant results with a 42.9% overall response rate in SS patients and an impressive median duration of response of 25.6 months. For MF patients, the study showed a 19.6% overall response rate with a median duration of response of 13.8 months. Notably, lacutamab was recently granted Breakthrough Therapy Designation by the FDA for Sézary syndrome treatment. The drug showed strong tolerability and effectiveness in heavily pretreated patients, with anti-tumor activity observed across all patients regardless of KIR3DL2 expression levels. The company is now preparing for a Phase 3 trial to advance this promising therapy.

Innate Pharma (NASDAQ: IPHA) announced the selection of four abstracts featuring its clinical development drugs for presentation at the ASCO 2025 Annual Meeting (May 30-June 3, 2025). The presentations include long-term follow-up data from the TELLOMAK Phase 2 trial studying lacutamab in Sézary syndrome and mycosis fungoides patients, a trial in progress poster for IPH4502 in advanced solid tumors expressing Nectin-4, and AstraZeneca's poster on updated results from the NeoCOAST-2 Phase 2 trial of monalizumab in resectable non-small-cell lung cancer (NSCLC).

Innate Pharma (NASDAQ: IPHA) announced the selection of abstracts for presentation at the European Hematology Association (EHA) Congress 2025 in Milan, Italy. The first abstract features IPH6501, their ANKET® therapy targeting CD20 B cells for relapsed/refractory Non-Hodgkin Lymphoma, which will be presented in a poster session on June 14, 2025. Additionally, an abstract about SAR'514/IPH6401, developed in partnership with Sanofi for Multiple Myeloma treatment, was accepted for online publication.

Innate Pharma (IPHA) reported Q1 2025 business update with significant pipeline developments. Key highlights include a €15 million investment from Sanofi and pipeline progress across multiple programs. The company achieved a major milestone with FDA Breakthrough Therapy Designation for lacutamab in treating relapsed/refractory Sézary syndrome. The first patient was dosed in Phase 1 study for IPH4502, their Nectin-4 ADC candidate for advanced solid tumors. Financial position remains strong with €72.5 million cash position as of March 31, 2025 (excluding €15M from Sanofi), extending runway to mid-2026. Notable developments in their ANKET® platform include ongoing trials for IPH6501 in B-NHL and strategic changes in the Sanofi partnership, including the termination of the 2016 agreement for IPH6101 and refocusing of SAR'514/IPH6401 towards autoimmune indications.

Innate Pharma (IPHA) has disclosed its latest share and voting rights data as of May 5, 2025. The company's share structure includes 92,176,373 ordinary shares, along with 6,489 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. The difference between theoretical and exercisable voting rights is due to treasury shares with suspended voting rights. The AGAP 2016 shares carry specific voting rights (130 for AGAP 2016-1 and 111 for AGAP 2016-2), while AGAP 2017 shares have no voting rights attached.

Innate Pharma (IPHA) has scheduled a conference call and webcast for Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT to provide a business update for Q1 2025. Key executives participating in the call include CEO Jonathan Dickinson, CMO Sonia Quaratino, COO Yannis Morel, and CFO Frédéric Lombard.

The company's management team will also conduct investor meetings in New York and Boston from May 13-14, 2025. The webcast will be accessible through the company's website, with a replay available for 90 days following the event.

Innate Pharma has announced the filing of two important regulatory documents for the year ending December 31, 2024. The company has submitted its 2024 Universal Registration Document to the French market authority (AMF) and its annual report on Form 20-F to the U.S. Securities and Exchange Commission (SEC).

The Universal Registration Document, available in French, can be accessed through both the company's website and the AMF's website. Similarly, the Form 20-F annual report is accessible via Innate Pharma's website and the SEC's website.

Innate Pharma, which trades on both Euronext Paris (IPH) and Nasdaq (IPHA), completed these filings on April 30, 2025, fulfilling its regulatory obligations in both European and American markets.

Innate Pharma presented new preclinical data for IPH4502, their novel antibody drug conjugate targeting Nectin-4, at the AACR 2025 Annual Meeting. The drug showed superior anti-tumor activity compared to enfortumab vedotin (EV) in various cancer models.

Key findings include:

• Better performance in urothelial carcinoma models with low Nectin-4 expression
• Effectiveness against EV-resistant tumors
• Strong activity in multiple cancers including triple-negative breast cancer, head and neck, and esophageal cancers

IPH4502 is currently in Phase 1 clinical trials for advanced solid tumors, with initial clinical data expected in 2026. The drug's enhanced internalization, cytotoxicity, and bystander killing effect suggest potential improved clinical benefits in areas with unmet medical needs.

Innate Pharma (Nasdaq: IPHA) has disclosed its latest share and voting rights data as of April 25, 2025. The company reported 92,175,723 ordinary shares outstanding, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. The theoretical voting rights include those attached to AGAP 2016, comprising 130 voting rights for AGAP 2016-1 and 111 voting rights for AGAP 2016-2, while AGAP 2017 carries no voting rights.